Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Combined Resveratrol for HBeAg Positive Chronic Hepatitis B
NCT03546530Phase 2Completed
- Sponsor
- The First Hospital of Jilin University
- Start
- Jun 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of resveratrol in Chronic Hepatitis B (CHB) (2 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: HBeAg seroconversion rate at 48 weeks. Started Jun 2016; status: completed.
02
Drugs
resveratrol
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03546530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546530.